Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | HPGD | P15428 | 2/20 | 0.53 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | CISD2 | Q8N5K1 | 1/20 | 0.47 |
| ▸ | RAF1 | P04049 | 8/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.42 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CASP7 | P55210 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3647679 | 0.82 | GAA (0.63) | GAAALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL28359916 | 0.82 | GAA (0.40) | GAAALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL167135 | 0.81 | RAF1 (0.45) | MAPTRAF1MAPK14MAPK13MAPK12 | |
| SCHEMBL3552066 | 0.80 | KMT2A (0.47) | GAAALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL3246252 | 0.80 | IKBKB (0.46) | GAAALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL9806950 | 0.80 | CISD2 (0.57) | GAAALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL2181959 | 0.77 | ALDH1A1 (0.57) | GAAALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL3242997 | 0.76 | RAF1 (0.38) | GAAALDH1A1MAPTHPGDMEN1 | |
| SCHEMBL173108 | 0.76 | RAF1 (0.56) | MAPTRAF1MAPK14KDM4EMAPK13 | |
| Hydrochloric Acid SCHEMBL10734949 | 0.75 | ALDH1A1 (0.55) | GAAALDH1A1MAPTHPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178780-A1 | RAF KINASE INHIBITORS | WOOD JILL E (US) | 2012-07-12 | — | — | US | disclosed |
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | RANGES GERALD | 2010-06-24 | — | — | US | disclosed |
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | RANGES GERALD | 2010-06-24 | — | — | US | disclosed |
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | RANGES GERALD | 2010-06-24 | — | — | US | disclosed |
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7741479-B2 | Urea inhibitors of MAP kinases | LOCUS PHARMACEUTICALS, INC. (US) | 2010-06-22 | — | — | US | disclosed |
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7713966-B2 | Heterobicyclic metalloprotease inhibitors | ALANTOS PHARMACEUTICALS HOLDING, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-20100063088-A1 | Raf Kinase Inhibitors | WOOD JILL E | 2010-03-11 | — | — | US | disclosed |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | LOCUS PHARMACEUTICALS, INC. (US) | 2010-02-18 | — | — | US | disclosed |
| US-20020103253-A1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION (US) | 2002-08-01 | — | — | US | disclosed |
| US-6344476-B1 | Inhibition of p38 kinase activity by aryl ureas | BAYER CORPORATION | 2002-02-05 | — | — | US | disclosed |
| US-20010006975-A1 | Raf kinase inhibitors | BAYER CORPORATION AND ONYX PHARMACEUTICALS WEST HAVEN, CT AND RICHMOND, CA, RESPECTIVELY | 2001-07-05 | — | — | US | disclosed |
| EP-0986382-A4 | RAF KINASE INHIBITORS | BAYER AG (US) | 2001-04-11 | — | — | EP | disclosed |
| US-6187799-B1 | TREATING CANCEROUS CELL GROWTH MEDIATED BY RAF KINASE BY ADMINISTERING SPECIFIED COMPOUNDS, SUCH AS 2-(METHYOXYCARBONYL),3-((4-METHYLPHENYL)UREA),5-ALKYL-THIOPHENE | ONYX PHARMACEUTICALS | 2001-02-13 | — | — | US | disclosed |
| EP-1019040-A4 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | BAYER AG (US) | 2000-10-04 | — | — | EP | disclosed |
| EP-1019040-A1 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | Bayer Corporation (US) | 2000-07-19 | — | — | EP | disclosed |
| EP-0986382-A1 | RAF KINASE INHIBITORS | Bayer Corporation (US) | 2000-03-22 | — | — | EP | disclosed |
| WO-1998052558-A1 | INHIBITION OF p38 KINASE ACTIVITY BY ARYL UREAS | BAYER CORPORATION (US) | 1998-11-26 | — | — | WO | disclosed |
| WO-1998052559-A1 | RAF KINASE INHIBITORS | BAYER CORPORATION (US) | 1998-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020103253-A1 | Inhibition of p38 kinase activity by aryl ureas | MAPK1, MAP3K1, MAP3K7 | GAA 461/4885ALDH1A1 1139/4885MAPT 638/4885 |
| US-20100160371-A1 | INHIBITION OF P38 KINASE ACTIVITY BY ARYL UREAS | MAPK1, MAP3K1, MAP3K7 | GAA 461/4885ALDH1A1 1139/4885MAPT 638/4885 |
| US-20100063088-A1 | Raf Kinase Inhibitors | BRAF, RAF1, ARAF | GAA 2980/4885ALDH1A1 2732/4885MAPT 3419/4885 |
| US-20120178780-A1 | RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | GAA 2980/4885ALDH1A1 2732/4885MAPT 3419/4885 |
| US-20100041642-A1 | UREA INHIBITORS OF MAP KINASES | MAP4K2, MAP3K1, MAP3K20 | GAA 1948/4885ALDH1A1 3577/4885MAPT 105/4885 |
| US-20010006975-A1 | Raf kinase inhibitors | BRAF, RAF1, ARAF | GAA 2980/4885ALDH1A1 2732/4885MAPT 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.